TYRA-200 for advanced FGFR2-altered bile duct cancer
Part of Bones, joints & muscles, Cancer, Genetic & congenital clinical trials.
This trial tests an experimental drug, TYRA-200, for people with advanced bile duct cancer whose tumors have a specific FGFR2 gene change and who have already tried another FGFR inhibitor. It aims to see if the drug is safe and can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your daily activities are not limited much by your cancer (ECOG 0 or 1).
- You have bile duct cancer (intrahepatic cholangiocarcinoma) with an FGFR2 gene change (mutation or rearrangement).
- You have already received at least one previous FGFR inhibitor treatment.
- You have a specific resistance mutation in the FGFR2 gene confirmed by a certified lab test.
- You have at least one tumor that can be measured on scans (RECIST 1.1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new kind of gene therapy (called HNF4α srRNA) given through a vein for people with advanced intrahepatic cholangiocarcinoma, a type of liver cancer that has stopped responding to standard chemotherapy. The goal is to see if it is safe and if it can help slow or stop the cancer.
This trial tests a new drug called TR-002 in people with advanced solid tumors (cancer that has spread) who have run out of standard treatment options. It includes a specific group for people with pancreatic cancer that is no longer responding to chemotherapy.
This trial tests an oral drug called TYRA-430 for people with advanced liver cancer (HCC) or other solid tumors that have changes in the FGF/FGFR pathway. It aims to see how safe the drug is and whether it can shrink tumors or slow cancer growth.
This study tests an experimental pill called TYRA-300 for people with low-grade bladder cancer that hasn't spread into the muscle layer. The pill targets a specific gene change (FGFR3) found in the tumor. The goal is to see if it can slow or shrink the cancer.
This trial tests different treatments for advanced bile duct or gallbladder cancer based on individual tumor features. It may help people who have not had prior therapy for their cancer.
This trial tests a new targeted drug (SHR-A1904) in people with advanced biliary tract cancer whose tumors have a specific protein (Claudin18.2) and who have already tried at least one standard treatment. The goal is to see if this drug can shrink the cancer or slow its growth.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.